A high-yielding and scalable phosphoramidite procedure was developed for the phospholipidation of TLR7/8-active imidazoquinolines. This method involves the reaction of a 1,2-diacyl- or dialkyl--glycerol or 3-chlolesterylalkanol with 2-cyanoethyl ,,','-tetraisopropylphosphordiamidite in the presence of -tetrazole followed by treatment of the resulting ,'-diisopropylphosphoramidite lipid in situ with 1-imidazoquinolinylalkanols. The resulting phosphite can be purified or directly oxidized with -butyl hydroperoxide. The cyanoethyl protecting group is then removed with triethylamine and the phospholipidated imidazoquinoline products isolated in good yield and purity by simple filtration.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451945 | PMC |
http://dx.doi.org/10.1016/j.tetlet.2016.03.091 | DOI Listing |
Tetrahedron Lett
May 2016
GSK Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, USA.
A high-yielding and scalable phosphoramidite procedure was developed for the phospholipidation of TLR7/8-active imidazoquinolines. This method involves the reaction of a 1,2-diacyl- or dialkyl--glycerol or 3-chlolesterylalkanol with 2-cyanoethyl ,,','-tetraisopropylphosphordiamidite in the presence of -tetrazole followed by treatment of the resulting ,'-diisopropylphosphoramidite lipid in situ with 1-imidazoquinolinylalkanols. The resulting phosphite can be purified or directly oxidized with -butyl hydroperoxide.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!